Coronavirus. Johnson & Johnson begins Phase 3 of its vaccine against Covid-19: "It is a feat"
Covid. "We already have 40 pre-selected volunteers for the Spanish trial of the anticovid vaccine"
The
single-dose vaccine
being tested by the pharmaceutical company Johnson & Johnson, through its Janssen subsidiary, has produced a strong immune response against the
coronavirus
according to the preliminary results of an early phase clinical trial (phase I / IIa), which have been published this Friday.
The vaccine, called Ad26.COV2.S, has been equally well tolerated at two different doses, based on known results.
The option of a single injection, compared to the two tested by Moderna and Pfizer, could facilitate its distribution.
However,
it is still not clear whether the older population
, one of the risk groups for Covid-19, will be protected to the same degree as the young population with the J&J vaccine.
The results released Friday refer to a
trial of nearly 1,000 healthy adults
, backed by the US government, that began after it was successfully tested in monkeys in July.
Preliminary results have been published on the medRxiv medical site, but have
not yet been reviewed by other researchers
.
From them, J&J has started this week a
phase III trial with 60,000 people
that can accelerate its future approval.
The company expects these new results by the end of this year or the beginning of 2021.
The Janssen researchers say that 98% of the participants from whom they obtained data had
generated, 29 days after the vaccine, neutralizing antibodies
, which defend the cells from infection.
However, the fact that the answer is only known in 15 people over 65 years of age limits the
interpretation for that age group
.
Side effects
It is known that for this group (over 65 years) the rate of adverse side effects such as fatigue and
muscle pain was 36%, well below the 64% obtained in the youngest volunteers
, which suggests that the immune response could not be as effective in the elderly.
Researchers hope to learn more details about safety and effectiveness when the current study is completed.
Dr. Barry Bloom, a professor at Harvard's TH Chan School of Public Health, has assured Reuters that
tests are
still
needed in larger groups
to find out these side effects.
"The vaccine has behaved as expected if you are going to go to phase III trials," she said.
It so happens that
volunteers in three Spanish hospitals
are
participating
in the phase III trial of this vaccine
: La Paz and La Princesa, in Madrid, and the Marqués de Valdecilla, in Santander.
According to the criteria of The Trust Project
Know more
Coronavirus
Covid 19
Vaccinations
HealthThe cold could protect you from Covid
Coronavirus: China's Sinovac vaccine against Covid-19 may be massively applied in early 2021
Health "There has been no volunteer discharge despite the side effect of AstraZeneca"
See links of interest
News
Translator
Programming
Horoscope
Films
Topics
Holidays Madrid 2021
Valencia Basket - MoraBanc Andorra
Coosur Real Betis - Club Joventut de Badalona
San Pablo Burgos - Herbalife Gran Canaria
Real Madrid - Casademont Zaragoza